Table 11 Current ongoing early phase I/II trials with ADC
From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
ADC | ||||
|---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
CAB-ROR2-ADC | Anti-ROR2 ADC | NCT03504488 (1/2) | Monotherapy | Advanced solid tumors including NSCLC |
Cofetuzumab Pelidotin | PTK7 ADC | NCT04189614 (1b) | Monotherapy | PTK7-expressing recurrent NSCLC |
DS-1062a | ADC targeting TROP2 | NCT04612751 (1) | Combination with Durvalumab | Advanced NSCLC with progression on chemotherapy and immunotherapy |
MGC018 | ADC delivers Duocarmycin | NCT03729596 (1/2) | Monotherapy and combination with MGA012 (anti-PD1 | Advanced solid tumors including NSCLC |
U3-1402 (Patritumab deruxtecan) | Drug (MAAA-1181a) linked to AB (Patritumab) | NCT03260491 (1) | Monotherapy | Advanced NSCLC with acquired resistance to EGFR TKI |